The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
SOHO 2020 | ClonoSEQ: evaluating MRD in CLL
Nitin Jain, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, outlines the importance of minimal residual disease (MRD) measurement in chronic lymphocytic leukemia (CLL), especially those treated with combination BTK inhibitor and venetoclax. Dr Jain outlines next-generation sequencing assays for MRD, including the ClonoSEQ assay, recently approved for clinical use in CLL patients by the FDA. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
